在 Venetoclax 治疗慢性淋巴细胞白血病的进展中，出现了 BCL2 多个突变与 Gly101Val 共存的情况。
Multiple BCL2 mutations cooccurring with Gly101Val emerge in chronic lymphocytic leukemia progression on venetoclax.
机构信息
Department of Pathology, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia.
Clinical Haematology, The Royal Melbourne Hospital and Peter MacCallum Cancer Centre, Parkville, VIC, Australia.
出版信息
Blood. 2020 Mar 5;135(10):773-777. doi: 10.1182/blood.2019004205.
Abstract
There is a Commentary on this article in this issue.
摘要
本期有对此文的评论。
相似文献
1
Multiple BCL2 mutations cooccurring with Gly101Val emerge in chronic lymphocytic leukemia progression on venetoclax.
Blood. 2020 Mar 5;135(10):773-777. doi: 10.1182/blood.2019004205.
2
Acquisition of the Recurrent Gly101Val Mutation in BCL2 Confers Resistance to Venetoclax in Patients with Progressive Chronic Lymphocytic Leukemia.
Cancer Discov. 2019 Mar;9(3):342-353. doi: 10.1158/2159-8290.CD-18-1119. Epub 2018 Dec 4.
3
Venetoclax resistance and acquired mutations in chronic lymphocytic leukemia.
Haematologica. 2019 Sep;104(9):e434-e437. doi: 10.3324/haematol.2019.222588. Epub 2019 Apr 19.
4
Novel BCL2 mutations in venetoclax-resistant, ibrutinib-resistant CLL patients with BTK/PLCG2 mutations.
Blood. 2020 Jun 11;135(24):2192-2195. doi: 10.1182/blood.2019003722.
5
Genomics of Resistance to Targeted Therapies.
Hematol Oncol Clin North Am. 2021 Aug;35(4):715-724. doi: 10.1016/j.hoc.2021.03.004. Epub 2021 May 26.
6
Potential of BCL2 as a target for chronic lymphocytic leukemia treatment.
Expert Rev Hematol. 2018 May;11(5):391-402. doi: 10.1080/17474086.2018.1456332. Epub 2018 Mar 29.
7
Structures of BCL-2 in complex with venetoclax reveal the molecular basis of resistance mutations.
Nat Commun. 2019 Jun 3;10(1):2385. doi: 10.1038/s41467-019-10363-1.
8
Venetoclax (Venclexta) for chronic lymphocytic leukemia.
Med Lett Drugs Ther. 2016 Aug 1;58(1500):101-2.
9
Landscape of Resistance Mutations in a Real-World Cohort of Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia Treated with Venetoclax.
Int J Mol Sci. 2023 Mar 18;24(6):5802. doi: 10.3390/ijms24065802.
10
Venetoclax, the first BCL-2 inhibitor for use in patients with chronic lymphocytic leukemia.
Clin Adv Hematol Oncol. 2019 Aug;17(8):440-443.
引用本文的文献
1
Superoxide-mediated phosphorylation and stabilization of Mcl-1 by AKT underlie venetoclax resistance in hematologic malignancies.
Leukemia. 2025 Jul 24. doi: 10.1038/s41375-025-02694-4.
2
Resistance to targeted therapies in chronic lymphocytic leukemia: Current status and perspectives for clinical and diagnostic practice.
Leukemia. 2025 Jun 24. doi: 10.1038/s41375-025-02662-y.
3
Mutations and translocations associated with venetoclax resistance in chronic lymphocytic leukemia.
Leukemia. 2025 Jun 23. doi: 10.1038/s41375-025-02611-9.
4
Development of a Novel Biomarker Platform for Profiling Key Protein-Protein Interactions to Predict the Efficacy of BH3-Mimetic Drugs.
Cancers (Basel). 2025 May 31;17(11):1852. doi: 10.3390/cancers17111852.
5
upregulation via aurora kinase inhibition overcomes primary failure to venetoclax in rearranged lymphomas.
iScience. 2025 May 2;28(6):112584. doi: 10.1016/j.isci.2025.112584. eCollection 2025 Jun 20.
6
Emergent BAX-mutated clonal hematopoiesis after venetoclax-based therapy for breast cancer.
Blood Adv. 2025 Sep 9;9(17):4391-4395. doi: 10.1182/bloodadvances.2025016063.
7
BCL-2 mutant B7H6-CAR-T cells synergized with venetoclax for treating small cell lung cancer.
J Immunother Cancer. 2025 May 7;13(5):e010073. doi: 10.1136/jitc-2024-010073.
8
Characteristics and outcomes of patients with double refractory and double exposed chronic lymphocytic leukemia.
Blood Adv. 2025 Jun 10;9(11):2808-2817. doi: 10.1182/bloodadvances.2025016006.
9
Improving Treatment Options for Patients with Double Refractory CLL.
Cancers (Basel). 2025 Jan 27;17(3):430. doi: 10.3390/cancers17030430.
10
BCL-2 inhibitors in hematological malignancies: biomarkers that predict response and management strategies.
Front Oncol. 2025 Jan 21;14:1501950. doi: 10.3389/fonc.2024.1501950. eCollection 2024.
本文引用的文献
1
Acquisition of the recurrent Gly101Val mutation in confers resistance to venetoclax in patients with progressive chronic lymphocytic leukemia ().
Haematologica. 2019 Nov;104(11):e540. doi: 10.3324/haematol.2019.232835.
2
Mitochondrial Reprogramming Underlies Resistance to BCL-2 Inhibition in Lymphoid Malignancies.
Cancer Cell. 2019 Oct 14;36(4):369-384.e13. doi: 10.1016/j.ccell.2019.08.005. Epub 2019 Sep 19.
3
Polyclonal Heterogeneity: The New Norm for Secondary Clinical Resistance to Targeted Monotherapy in Relapsed Leukemia?
Cancer Discov. 2019 Aug;9(8):998-1000. doi: 10.1158/2159-8290.CD-19-0575.
4
Venetoclax and Obinutuzumab in Patients with CLL and Coexisting Conditions.
N Engl J Med. 2019 Jun 6;380(23):2225-2236. doi: 10.1056/NEJMoa1815281. Epub 2019 Jun 4.
5
Structures of BCL-2 in complex with venetoclax reveal the molecular basis of resistance mutations.
Nat Commun. 2019 Jun 3;10(1):2385. doi: 10.1038/s41467-019-10363-1.
6
Efficacy of venetoclax in relapsed chronic lymphocytic leukemia is influenced by disease and response variables.
Blood. 2019 Jul 11;134(2):111-122. doi: 10.1182/blood.2018882555. Epub 2019 Apr 25.
7
Venetoclax resistance and acquired mutations in chronic lymphocytic leukemia.
Haematologica. 2019 Sep;104(9):e434-e437. doi: 10.3324/haematol.2019.222588. Epub 2019 Apr 19.
8
Acquisition of the Recurrent Gly101Val Mutation in BCL2 Confers Resistance to Venetoclax in Patients with Progressive Chronic Lymphocytic Leukemia.
Cancer Discov. 2019 Mar;9(3):342-353. doi: 10.1158/2159-8290.CD-18-1119. Epub 2018 Dec 4.
9
Venetoclax-Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia.
N Engl J Med. 2018 Mar 22;378(12):1107-1120. doi: 10.1056/NEJMoa1713976.
10
Clonal dynamics towards the development of venetoclax resistance in chronic lymphocytic leukemia.
Nat Commun. 2018 Feb 20;9(1):727. doi: 10.1038/s41467-018-03170-7.
Zotero 插件